eCARTv5 Clinical Deterioration Suite (“eCART”)

FDA 510(k) K233253 · Agilemd, Inc.

Substantially Equivalent

510(k) numberK233253

Submission

Device name
eCARTv5 Clinical Deterioration Suite (“eCART”)
Applicant
Agilemd, Inc.
San Francisco, CA, US
Received
September 28, 2023
Decision date
June 21, 2024
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
QNL – Medium-Term Adjunctive Predictive Cardiovascular Indicator
Device class
Class II (moderate risk)
Regulation
21 CFR 870.2210
Specialty
Cardiovascular

The adjunctive predictive cardiovascular indicator is a prescription device that uses software algorithms to analyze cardiovascular vital signs and predict future cardiovascular status or events within a defined medium-term period. This device is intended for adjunctive use with other physical vital sign parameters and patient information and is not intended to independently direct therapy.

Other 510(k)s with product code QNL

510(k)DeviceApplicantDecision
K233216CLEWICU SystemQNL · Traditional Clew Medical , Ltd.01/13/2024SE
K230842SignalHF (IM008)QNL · Traditional Implicity, Inc.10/25/2023SE
K231038Global Hypoperfusion Index (GHI) AlgorithmQNL · Traditional Edwards Lifesciences, LLC07/26/2023SE
K200717CLEWICU System (ClewICUServer and ClewICUnitor)QNL · Traditional Clew Medical , Ltd.01/09/2021SE

Questions and answers

When was eCARTv5 Clinical Deterioration Suite (“eCART”) cleared by the FDA?

eCARTv5 Clinical Deterioration Suite (“eCART”) (K233253) received a 510(k) decision of Substantially Equivalent on June 21, 2024, 267 days after the submission was received.

What is the product code of K233253?

The FDA product code is QNL – Medium-Term Adjunctive Predictive Cardiovascular Indicator, a Class II (moderate risk) device regulated under 21 CFR 870.2210.